TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma

Abstract Background The standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy (CRT) using 5-FU plus cisplatin. However, complete response (CR) rates are low at 11–25%, resulting in 9–10 months of median overall su...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Hideaki Bando, Daisuke Kotani, Takahiro Tsushima, Hiroki Hara, Shigenori Kadowaki, Ken Kato, Keisho Chin, Kensei Yamaguchi, Shun-ichiro Kageyama, Hidehiro Hojo, Masaki Nakamura, Hidenobu Tachibana, Masashi Wakabayashi, Miki Fukutani, Yosuke Togashi, Nozomu Fuse, Hiroyoshi Nishikawa, Takashi Kojima
Format:	Article
Language:	English
Published:	BMC 2020-04-01
Subjects:	Unresectable locally advanced Esophageal squamous cell carcinoma Chemoradiotherapy Atezolizumab
Online Access:	http://link.springer.com/article/10.1186/s12885-020-06716-5